| Cash Flow | 2026-02-28 | 2025-11-30 | 2025-08-31 |
|---|---|---|---|
| Net loss | -87,174 | -78,221 | -186,236 |
| Depreciation and amortization | 2,196 | 2,120 | 6,620 |
| Stock-based compensation | 9,404 | 9,086 | 28,879 |
| Net accretion of discount on marketable securities | 1,978 | 1,867 | 8,455 |
| Loss on disposal of property and equipment | -160 | -89 | NaN |
| Amortization of operating lease right-of-use assets | 1,580 | 2,511 | 7,605 |
| Other | NaN | 0 | 0 |
| Prepaid expenses and other assets | -1,287 | 1,284 | 4,945 |
| Accounts payable | -461 | 3,025 | -3,655 |
| Deferred revenue | -1,252 | -13,577 | -23,403 |
| Operating lease liabilities | 205 | -756 | -4,311 |
| Accrued expenses and other current liabilities | 4,119 | 11,042 | 6,268 |
| Net cash used in operating activities | -71,914 | -67,832 | -181,633 |
| Purchases of marketable securities | 255,934 | 174,338 | 281,350 |
| Maturities of marketable securities | 133,153 | 179,815 | 437,728 |
| Purchases of property and equipment | 1,045 | 5,131 | 8,871 |
| Net cash provided by (used in) investing activities | -123,826 | 346 | 147,507 |
| Proceeds from issuances of common stock and pre-funded warrants, net of issuance costs | NaN | 234,762 | 0 |
| Proceeds from exercise of stock options and pre-funded warrants | NaN | 1,651 | NaN |
| Proceeds from exercise of stock options | -30 | NaN | 405 |
| Proceeds from issuance of common stock under employee stock purchase plan | 1,596 | 0 | 2,229 |
| Proceeds from issuances of common stock in at the market financing, net of issuance costs | 18,004 | 0 | 0 |
| Repurchase of unvested early exercised stock options | NaN | 0 | 0 |
| Net cash provided by financing activities | 19,975 | 236,008 | 2,634 |
| Net decrease in cash, cash equivalents and restricted cash | -175,765 | 168,522 | -31,492 |
| Cash and cash equivalents at beginning of period | NaN | 79,406 | NaN |
| Cash, cash equivalents and restricted cash at beginning of period | 247,928 | NaN | 110,898 |
| Cash and cash equivalents at end of period | NaN | 247,928 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 72,163 | NaN | 79,406 |
Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. (NRIX)